Old Web
English
Sign In
Acemap
>
authorDetail
>
Al Spada
Al Spada
Internal medicine
Clinical trial
Caspase 3
Gastroenterology
Fatty liver
4
Papers
73
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease
2019
Mitchell L. Shiffman
Bradley Freilich
Raj Vuppalanchi
Kymberly D. Watt
Jean L. Chan
Al Spada
David T. Hagerty
Eugene R. Schiff
Show All
Source
Cite
Save
Citations (0)
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease
2019
Alimentary Pharmacology & Therapeutics
Mitchell L. Shiffman
Bradley Freilich
Raj Vuppalanchi
Kymberly D. Watt
Jean L. Chan
Al Spada
David T. Hagerty
Eugene R. Schiff
Show All
Source
Cite
Save
Citations (44)
Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation
2018
Journal of Molecular Medicine
Akiko Eguchi
Yukinori Koyama
Alexander Wree
Casey D. Johnson
Ryota Nakamura
Davide Povero
David Boulos Kneiber
Masahiko Tameda
Patricia Contreras
Al Spada
Ariel E. Feldstein
Show All
Source
Cite
Save
Citations (15)
Induction of heat shock protein 70 by herbimycin A and cyclopentenone prostaglandins in smooth muscle cells
2000
Cell Stress & Chaperones
L T Hamel
Margaret Kenney
Zaid Jayyosi
Ali Ardati
Kenneth Lyle Clark
Al Spada
Asher Zilberstein
Mark H. Perrone
June Kaplow
Linda Merkel
Camilo Rojas
Show All
Source
Cite
Save
Citations (14)
1